Clean Biologics Targets Asia's $1.5B Biotech Market with End-to-End Service

NANTES, France – April 13, 2026 – As South Korea solidifies its position as a global biopharmaceutical powerhouse, two European life science firms are making a strategic push into the heart of Asia's innovation hub. Sister companies Clean Cells and Naobios, under the Clean Biologics group, have announced their attendance at the upcoming BIO KOREA 2026 conference, signaling a significant move to deepen their engagement with the region's burgeoning cell and gene therapy (CGT) and vaccine markets.

The French duo aims to showcase a comprehensive, end-to-end service model that combines Naobios's specialized manufacturing of viral vectors and vaccines with Clean Cells's robust quality control and biosafety testing. This integrated offering is designed to de-risk and accelerate the complex journey of advanced therapies from the laboratory to clinical trials, a proposition they believe is perfectly timed for South Korea's ambitious growth trajectory.

Tapping into South Korea’s Biopharma Boom

The decision to focus on South Korea is backed by compelling market dynamics. The country's cell and gene therapy manufacturing sector alone is projected to skyrocket to a revenue of over $1.5 billion by 2030, expanding at a staggering compound annual growth rate (CAGR) of nearly 27%. This explosive growth is no accident; it is the result of a concerted national effort.

The South Korean government has identified biotechnology as a cornerstone of its future economy, launching ambitious initiatives like the "Bioeconomy 2030" strategy. This includes massive public investment, with over $1.2 billion allocated specifically for regenerative medicine and cell therapy projects, including the development of critical quality control infrastructure. This government backing, combined with a surge in innovator drug licensing deals totaling nearly $8 billion in 2025, has transformed the nation into a hotbed for advanced therapeutic development.

“South Korea is one of the most dynamic CGT and vaccine markets in Asia,” said François Pedelaborde, business development director at Clean Cells. “We are delighted to attend BIO KOREA to meet existing and future clients and strengthen our long-term commitment in the country and more widely in Asia.”

Clean Cells, with over 25 years of experience and credentials including EMA GMP certification and FDA inspections, is poised to support this expansion by providing essential analytical services that help local biopharma companies meet global regulatory standards, a crucial step for any firm with international ambitions.

The Integrated Advantage in a Competitive Landscape

While global contract development and manufacturing organizations (CDMOs) like Lonza, Catalent, and WuXi Biologics have a strong presence in Asia, Clean Biologics is betting on the unique synergy between its subsidiaries to carve out a niche. The group's 'end-to-end' claim is built on a seamless workflow where Naobios develops and manufactures complex viral products—often in high-containment BSL2 and BSL3 facilities—while Clean Cells provides concurrent, in-house quality control and safety testing.

This model directly addresses a common bottleneck in drug development: the logistical and quality assurance challenges of managing separate manufacturing and testing vendors. By keeping these critical functions under one group, the company aims to reduce timelines, minimize the risk of cross-contamination or batch failure, and provide clients with a single point of accountability from proof-of-concept through to GMP-grade clinical batch production.

The competitive field is fierce, with local South Korean players like SK Pharmteco and emerging specialists such as Dr. Park CDMO also vying for market share. However, the specific combination of Naobios's two decades of experience in live viruses and Clean Cells's extensive regulatory testing expertise provides a powerful and, as the company claims, 'rare' value proposition for developers of viral vaccines, oncolytic viruses, and gene therapies.

Driving Global Health Through Strategic Partnerships

The company’s expertise is not just theoretical; it is already being applied in high-stakes projects across Asia. Naobios has a proven track record, most notably through its partnership with the Korean-Canadian firm Creo SG Co., Ltd. (formerly Sumagen). The collaboration is focused on optimizing an innovative HIV vaccine candidate for industrial-scale production within Naobios's highly specialized BSL3 facilities.

Seung Ho Choo, Executive Director of R&D at Creo SG, highlighted the value of the partnership. “Naobios possesses differentiated BSL3 facilities and advanced technical capabilities, and its close, efficient communication enables proactive and effective problem-solving,” he stated, noting that the group's in-house analytical capabilities enhance overall production efficiency. The project recently achieved a key milestone with successful bench-scale production, paving the way for GMP manufacturing and Phase I/II clinical trials.

Beyond HIV, Naobios is also collaborating with the Tokyo Metropolitan Institute of Medical Science to develop a novel live-attenuated vaccine against mpox. This project, spurred by the global outbreak that began in 222, aims to create a safer vaccine alternative. These Asian partnerships, alongside collaborations with US-based FluGen and the Gates Foundation, underscore the company's role as a key enabler of global health solutions.

A Calculated Global Expansion

The move into South Korea is a deliberate step in a broader global strategy orchestrated by the parent company, Clean Biologics. Since being established in 2018 with backing from the ARCHIMED fund, the group has systematically expanded its capabilities through strategic acquisitions. The addition of Naobios in 2019, followed by North American expansions with Biodextris in Canada and KaryoLogic in the United States, has built a transatlantic service network.

This methodical growth has created a CTDMO (Contract Testing, Development, and Manufacturing Organization) capable of serving clients across key global markets. The push into Asia, therefore, represents the next logical phase of this expansion. By establishing a stronger foothold in the region, Clean Biologics is positioning itself to support the next wave of biopharmaceutical innovation, wherever it may emerge.

As representatives from Clean Cells and Naobios prepare to engage with potential partners at booth #F32 during BIO KOREA, they carry with them not just a service catalog, but a demonstrated history of enabling cutting-edge science and a clear vision for their role in the future of medicine.